IndiTreat ® test effectiveness

IndiTreat® – The potential to predict tumor resistance and sensitivity

Until today, there have been no functional means to evaluate the most efficacious form of cancer treatment for the individual patient. Up to 50% of first-line treatments of metastatic colorectal cancer are ineffective mainly due to tumor resistance*, causing a measurable burden on clinic resources and immeasurable patient suffering.

Over the last decade, testing cancer treatments on microtumors rather than on the patient has been on the horizon. With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality. IndiTreat serves you and your clinic with functional information on tumor resistance and sensitivity.

* European Journal of Cancer 81 (2017) 191–202

What does this mean to oncologists and their patients?

The potential to predict tumor resistance and sensitivity to cancer drugs

The power to select the most appropriate treatment, in accordance with guidelines or off-label

The promise to improve patient quality of life through in vitro testing of drug efficacy on the individual patient

Want to know more?

Want to know more?

Contact us

Please contact 2cureX for more information

Email: info@2cureX.com
Phone: +45 22115399
Web: www.IndiTreat.com

Upcoming events

October 21, 2021

Presentation by Henrik Harling (CMO 2cureX) at the 17. National Congress of Digestive Cancers (Viseu, Portugal)

Read more

November 15, 2021

Presentation by Ole Thastrup (CSO 2cureX) at the TechConnect Europe Innovation Conference & Expo (Malmø, Sweden)

Read more

November 25, 2021

Q3 2021 Interim Report released

View previous reports

February 24, 2022

Year-End Report 2021

View previous reports

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs